



18th January 2016

BG's Wake Up Call

	Last close	Daily chg (%)	Chg YTD (%)
Indices			
Dow Jones	15988.08	-2.39%	-10.30%
S&P 500	1880.33	-2.16%	-8.67%
Nasdaq	4488.42	-2.74%	-5.23%
Nikkei	16955.57	-1.12%	-1.74%
Stoxx 600	329.84	-2.82%	-3.71%
CAC 40	4210.16	-2.38%	-1.46%
Oil /Gold			
Crude WTI	29.7	-4.93%	-44.82%
Gold (once)	1090.15	+0.72%	-8.11%
Currencies/Rates			
EUR/USD	1.0952	+1.04%	-9.49%
EUR/CHF	1.09385	+0.05%	-9.02%
Euribor	-0.142	-0.70%	-282.05%

Economic releases :

Date

18th-Jan	US - Markets closed.
	GB - Rightmove House prices Jan. (6.5% act.)
	JP - Tertiary Industry Index Jan. (-0.8% act. 0.7% exp.)

Upcoming BG events :

Date

2nd-Mar	ALBIOMA (BG Paris Lunch CEO)
10th-Mar/ 11th-Mar	BG TMT Conference
23rd-Mar	EIFFAGE (BG Luxembourg with IR)
28th-Apr	ORPEA (BG Luxembourg with IR)

Recent reports :

Date

13th-Jan	A spicer dish (Nestlé, coverage initiation)
14th-Dec	ATOS Synergies before organic growth
7th-Dec	ARM HOLDING - Cash me if you can
3rd-Dec	Luxury Goods, Buying opportunities despite volatile environment!
30th-Nov	Environmental Services It is time to take a rest on Veolia!
25th-Nov	Food retailing Anorexic growth... the bigger the better!

List of our Reco & Fair Value : Please click here to download



EDF

NEUTRAL, Fair Value EUR18,5 vs. EUR18 (+56%)

Lower than expected impact of Cigeo costs on the group's provisions

Last Friday after market, in a letter sent to the Chairman and CEO of EDF, the Chairman of Areva and the General Administrator of CEA, the Ministry of Ecology and Sustainable Development and Energy attached a Ministerial order concerning the cost associated with the Cigéo project. The new cost set by this order stands at EUR25bn under economic conditions in 2011 and is to substitute the estimates benchmark of EUR20.8bn on which the EDF group based its 2014 and interim 2015 accounts. This substitution has a positive impact on our FV as we were assuming a higher adjustment. Positive.

HUGO BOSS

NEUTRAL, Fair Value EUR103 vs. EUR107 (+42%)

Reassuring Q4 organic growth at the expense of margins

Last Friday Hugo Boss announced its preliminary FY15 results ahead of schedule. Investors preferred to see the glass half full (i.e. Q4 FX-n growth of 5% vs. BG and CS at ~3%) instead of retaining the margin miss (Q4 adj. EBITDA of EUR171 => ~8% below BG ests). Hugo Boss posted reassuring top line trends thanks to a robust performance in Europe (+10% FX-n), helped by more promotions though, while Americas and Asia-Pacific were less weak than in Q3. Following Burberry's trading statement last Thursday, this publication also shows that fears about the mild winter and travel cancellations were somewhat over-exaggerated. Ahead of the FY16 outlook which should be delivered on 10th March, we have notched down our FY16-17 adj. EBITDA assumptions by 3% on average, leading to our FV of EUR103 vs. EUR107.

CASINO GUICHARD

BUY, Fair Value EUR54 (+35%)

S&P update: a sledgehammer blow / self-fulfilling phenomenon

According to the latest information, against the backdrop of a challenging macroeconomic environment in emerging markets, and more especially Brazil, S&P placed Casino Group's BBB- under negative creditwatch on 15th January. Following Muddy Waters' report, one of the biggest challenges for Casino was to maintain the confidence of the market (shareholders and rating agencies) and to avoid of a self-fulfilling phenomenon. We believe that this is precisely what is happening (insofar as S&P does not seem to bring new very elements). The market now has to rely on Casino's strong track record in terms of asset disposals.

VIDEO GAMES

US packaged software sales in December and CY15

The NPD Group has released data for December's packaged video games sales in the US. Hardware sales were down 3% Y/Y in Dec. and 2% in CY15 (the PS4 was the top-selling console for the 10th time). Packaged software was down 6% in Dec. and 4% in CY15 (vs. BG ests: +5%e and stable), mainly due to declines in handheld and last generation consoles and the strong trend towards digital. Activision Blizzard's Call of Duty: Black Ops III was the best-selling game. Note that calendar Q4 represented 49.2% of CY sales (Oct. 6.5%, Nov. 19.2% and Dec. 23.4%). We are making no change to recommendations for our sector coverage: Buy on UBISOFT with a FV of EUR37 and GAMELOFT with a FV of EUR6.7. Speculation has heightened now that Vivendi has sold its remaining 5.7% stake in Activision Blizzard (net proceeds of ~EUR1bn). We believe in this and our FVs reflect minimum prices for potential public offers.

In brief...

AXWAY SOFTWARE, Acquisition of Appcelerator

BONE THERAPEUTICS,

COFACE, Xavier Durand to replace Jean-Marc Pillu as CEO next month

PERNOD RICARD, Pernod Ricard gained US approval for Havana Club trademark

Utilities

EDF

Price EUR11.87

Lower than expected impact of Cigeo costs on the group's provisions

Fair Value EUR18,5 vs. EUR18 (+56%)

NEUTRAL

Bloomberg	EDF FP
Reuters	EDF.PA
12-month High / Low (EUR)	23.8 / 11.9
Market Cap (EUR)	22,792
Ev (BG Estimates) (EUR)	85,986
Avg. 6m daily volume (000)	2 332
3y EPS CAGR	-14.8%

	1 M	3 M	6 M	31/12/14
Absolute perf.	-7.6%	-29.4%	-42.5%	-48.0%
Utilities	-4.9%	-6.6%	-13.4%	-10.2%
DJ Stoxx 600	-8.3%	-8.6%	-17.5%	-3.7%

YEnd Dec. (EURm)	2014	2015e	2016e	2017e
Sales	72,874	75,765	76,950	78,169
% change		4.0%	1.6%	1.6%
EBITDA	17,279	17,343	16,356	16,498
EBIT	7,984	8,689	7,709	7,289
% change		8.8%	-11.3%	-5.5%
Net income	4,464	2,917	2,826	2,764
% change		-34.7%	-3.1%	-2.2%

	2014	2015e	2016e	2017e
Operating margin	11.0	11.5	10.0	9.3
Net margin	6.1	3.9	3.7	3.5
ROE	11.0	7.1	6.9	6.7
ROCE	3.4	3.7	3.2	2.9
Gearing	139.8	150.3	161.0	169.6

(EUR)	2014	2015e	2016e	2017e
EPS	2.40	1.57	1.52	1.49
% change	-	-34.7%	-3.1%	-2.2%
P/E	4.9x	7.6x	7.8x	8.0x
FCF yield (%)	NM	NM	NM	NM
Dividends (EUR)	1.25	1.25	1.25	0.99
Div yield (%)	10.5%	10.5%	10.5%	8.4%
EV/Sales	1.1x	1.1x	1.2x	1.2x
EV/EBITDA	4.6x	5.0x	5.6x	5.7x
EV/EBIT	10.0x	9.9x	11.8x	13.0x

Last Friday after market, in a letter sent to the Chairman and CEO of EDF, the Chairman of Areva and the General Administrator of CEA, the Ministry of Ecology and Sustainable Development and Energy attached a Ministerial order concerning the cost associated with the Cigéo project. The new cost set by this order stands at EUR25bn under economic conditions in 2011 and is to substitute the estimates benchmark of EUR20.8bn on which the EDF group based its 2014 and interim 2015 accounts. This substitution has a positive impact on our FV as we were assuming a higher adjustment. Positive.

ANALYSIS

- A new Cigeo cost set by the Ministry of Ecology and Sustainable Development and Energy:** Last Friday after market, in a letter sent to the Chairman and CEO of EDF, the Chairman of Areva and the General Administrator of CEA, the Ministry of Ecology and Sustainable Development and Energy attached a Ministerial order concerning the cost associated with the Cigéo project. The new cost set by this order stands at EUR25bn under economic conditions of 2011 and is to substitute the estimates benchmark of EUR20.8bn on which the EDF group based its 2014 and interim 2015 accounts. Taking into account this cost will therefore result in an increase of around EUR800m in provisions (EUR0.43/share impact) for long-term radioactive waste management for future expenses relating to Cigéo deep storage in EDF's consolidated accounts at the end of 2015. This increase in provisions is set to have a negative impact of around EUR500m post tax on net income group share in 2015 (-12.5% vs. our previous estimates). The group mentioned that EDF's Board of Directors would determine the impact of this provision on the dividend to be proposed at the General Shareholder's Meeting, based on 2015 consolidated financial statements.
- Impact for EDF?** While this adjustment is clearly negative for EDF as it will negatively alter the group's balance sheet compared with 2014, it has a positive impact on our FV as we were assuming a higher adjustment (EUR3bn negative impact on the group's provisions based on a Cigéo cost of EUR36bn). Readjusting our assumptions for Cigéo provisions (based on an SOTP, and a Dividend Yield & P/E model) prompts us to raise our FV from EUR18 to EUR18.5/share. As for dividend payment for 2015 we continue to assume EUR1.25/share and do not expect any negative adjustment in share terms, at least not based on this assumption change (non-cash effect). However, we were already assuming a decline in 2017 to EUR1/share based on earnings deterioration compared with 2014-15.
- Additional cost reductions in the pipe?** Over the weekend, the CFDT union announced that the group is working on a plan aimed at cutting 4,000 posts by 2018 (without compulsory redundancies), thereby reducing the group's workforce by 2.5%. No further details were unveiled, except that EDF is planning to set out this plan next Thursday. Based on the group's current average full wage charges (around EUR75k/employee/year) this could imply a positive impact of up to EUR300m on the group's costs structure by 2019 (+1.7% positive impact on EBITDA). Given the lack of details, we have not factored a positive impact from this plan into our model, although it is clearly positive.

VALUATION

- At the current share price, EDF is trading on 5.5x 2016e EBITDA and offers a 10.3% yield
- Neutral, FV @ EUR18.5

NEXT CATALYSTS

- 14th February 2016: EDF - 2015 earnings

[Click here to download](#)



Analyst :
 Xavier Caroen
 33(0) 1.56.68.75.18
 xcaroen@bryangarnier.com

Luxury & Consumer Goods

Hugo Boss

Price EUR72.74

Reassuring Q4 organic growth at the expense of margins

Fair Value EUR103 vs. EUR107 (+42%)

NEUTRAL

Bloomberg	BOSS GR
Reuters	BOSG_p.DE
12-month High / Low (EUR)	120.0 / 69.1
Market Cap (EURm)	5,121
Ev (BG Estimates) (EURm)	5,189
Avg. 6m daily volume (000)	256.9
3y EPS CAGR	6.0%

	1 M	3 M	6 M	31/12/14
Absolute perf.	-3.4%	-28.8%	-30.1%	-28.5%
Pers & H/H Gds	-7.1%	-8.5%	-10.3%	9.3%
DJ Stoxx 600	-8.3%	-8.6%	-17.5%	-3.7%

YEnd Dec. (EURm)	2014	2015e	2016e	2017e
Sales	2,572	2,809	2,962	3,138
% change		9.2%	5.4%	6.0%
EBITDA	571	609	633	688
EBIT	448.7	465.8	490.4	537.7
% change		3.8%	5.3%	9.6%
Net income	333.3	335.8	370.3	412.2
% change		0.8%	10.3%	11.3%

	2014	2015e	2016e	2017e
Operating margin	17.4	16.6	16.6	17.1
Net margin	13.0	12.0	12.5	13.1
ROE	39.5	35.2	31.8	29.5
ROCE	33.2	30.5	31.2	33.5
Gearing	5.1	7.2	-9.2	-22.6

(EUR)	2014	2015e	2016e	2017e
EPS	5.04	4.91	5.40	6.01
% change	-	-2.6%	10.0%	11.2%
P/E	14.4x	14.8x	13.5x	12.1x
FCF yield (%)	5.5%	6.1%	8.9%	10.2%
Dividends (EUR)	3.62	3.75	4.20	4.65
Div yield (%)	5.0%	5.2%	5.8%	6.4%
EV/Sales	2.0x	1.8x	1.7x	1.5x
EV/EBITDA	9.0x	8.5x	7.9x	7.0x
EV/EBIT	11.5x	11.1x	10.2x	8.9x

Last Friday Hugo Boss announced its preliminary FY15 results ahead of schedule. Investors preferred to see the glass half full (i.e. Q4 FX-n growth of 5% vs. BG and CS at ~3%) instead of retaining the margin miss (Q4 adj. EBITDA of EUR171 => ~8% below BG ests). Hugo Boss posted reassuring top line trends thanks to a robust performance in Europe (+10% FX-n), helped by more promotions though, while Americas and Asia-Pacific were less weak than in Q3. Following Burberry's trading statement last Thursday, this publication also shows that fears about the mild winter and travel cancellations were somewhat over-exaggerated. Ahead of the FY16 outlook which should be delivered on 10th March, we have notched down our FY16-17 adj. EBITDA assumptions by 3% on average, leading to our FV of EUR103 vs. EUR107.

ANALYSIS

- Q4 sales reached EUR750m, up 10% as reported and 5% FX-n (CS and BG: ~+3%e). Although the group achieved FX-n growth in the lower range of the FY guidance (+3-5% FX-n), the Q4 performance accelerated vs. Q3 (-1%) and topped expectations thanks to: (i) a robust growth in Europe (+10% FX-n vs. +4% in Q3), helped by higher rebates, (ii) a higher contribution from retail (~65% of total sales vs. 54% in Q3), which grew at 6% and (iii) a slight rebound in wholesale to 2% vs. -7% in Q3. Note that retail comp sales decreased by 1% in Q4 vs. flat in Q3.
- By region and in Q4 alone, Europe indeed posted better-than-expected growth (+10% FX-n) thanks to the UK and southern Europe, confirming also that Hugo Boss is a bit less exposed to travel cancellations for Europe as tourists only account for ~15% of European retail sales. As expected, the Americas remained weak (-1% vs. -7% in Q3) marked by a tough US market (double-digit decline). Last but not least, Asia-Pacific decreased by 7% (vs. -12% in Q3) given a double-digit decline in China although the group does not specify whether trends improved in Mainland China like for Burberry.

Sales growth per geography and distribution channel:

FX-neutral growth	Q3 15	9M 15	Q4 15	2015
Europe	4	5	10	5
Americas	-7	-1	-1	-1
Asia-Pacific	-12	-2	-7	-3
Retail FX-n / SSSG	6 / 3	8 / 3	6 / -1	7 / 2
Wholesale	-7	-4	2	-3
Total Hugo Boss	-1	3	5	3

Source: Company Data, BG ests

- Q4 adj EBITDA of EUR171m missed expectations (BG: EUR185m). This deviation is explained by: (i) the negative retail comp sales over Q4 (= operating leverage) and (ii) a higher rate of rebates vs. Q4 14 given adverse apparel market conditions (unfavourable weather and promotional). The adj. EBITDA margin dropped by 140bps to 23.1%. This difficult year-end led to a limited 1% increase in the adj. EBITDA for 2015, shy of the company's guidance (+3-5%).
- Cautious FY16 outlook: Ahead of the FY15 Results presentation on 10th March, the group has already declared that FX-n sales growth should be below the LT target of high single-digit (BG: +5.5%e) given the difficult US and Chinese markets. We have made no change to our top line assumptions but have notched down our adj. EBITDA forecasts by 3% on average for the 2016-17 period since we expect the group to remain affected by markdowns and by the US/China in H1 16 at least.

VALUATION

- This early publication should eventually appease fears about two significant headwinds (i.e. mild weather and a decline in tourist flows to Europe), which explains why investors focused more on these reassuring top line trends than on the margin miss, all the more since the stock has dropped by ~30% since the PW last October.

NEXT CATALYSTS

- Hugo Boss is to release its FY15 Results on 10th March.

[Click here to download](#)



Analyst:
Cédric Rossi
33(0) 1 70 36 57 25
rossi@bryangarnier.com

Consumer Analyst Team:
Nikolaas Faes
Loïc Morvan
Antoine Parison
Virginie Roumagne

Food retailing

Casino Guichard

Price EUR40.04

S&P update: a sledgehammer blow / self-fulfilling phenomenon

Fair Value EUR54 (+35%)

BUY

According to the latest information, against the backdrop of a challenging macroeconomic environment in emerging markets, and more especially Brazil, S&P placed Casino Group's BBB- under negative creditwatch on 15th January. Following Muddy Waters' report, one of the biggest challenges for Casino was to maintain the confidence of the market (shareholders and rating agencies) and to avoid of a self-fulfilling phenomenon. We believe that this is precisely what is happening (insofar as S&P does not seems to bring new very elements). The market now has to rely on Casino's strong track record in terms of asset disposals.

"Asset disposals are not ruled out" [...] "we will react, as usual, in real time to market expectations" said Mr Naouri during our latest RS in Paris (comments following our RS with CEO and CFO). Yet, in all evidence, Casino's indebtedness has become such a question mark, as evidenced by Muddy Waters, that management may have no choice but to take drastic measures through outright disposals of non-core assets. However, Casino has stated its intention to sell Big C which, along with Monoprix, finds a pro-eminent place amongst the crown jewels! This announcement could illustrate the degree of the company's distress. Today, S&P's announcement is likely to bring further pressure.

According to the latest information, against the backdrop of a challenging macroeconomic environment in emerging markets, and more especially Brazil, S&P placed Casino Group's BBB- under negative creditwatch on 15th January. At this stage, S&P anticipates that it may lower the rating by "not more than two notches". This announcement came after the group's CFO guided for 2015 underlying EBIT of around EUR1.5bn (vs EUR1.7bn expected by the consensus the day of this statement).

The rating agency emphasises the group's high indebtedness and the deterioration of the situation in Latin America, Asia and e-commerce operations, performances from which were below S&P's estimates. As a result, S&P expects rather weak financial metrics over 2016 and 2017 that could prevent Casino from improving its proportional leverage to 3.5x in 2016, in contrast to its prior expectations. The rating agency will soon conduct, in collaboration with Casino's management, a review of the Group's credit rating. As a reminder, in late 2015, Casino launched a disposal plan, initially of EUR2bn, which was increased to approximately EUR4bn with the planned sale of its Big C subsidiary listed in Thailand, following indications of interest from potential buyers.

ANALYSIS

- The group is now threatened by a potential downgrade to non investment grade (i.e. a category of investment which cannot be owned by large institutional investors). This announcement may come as a surprise (it comes after the reiteration of Casino's outlook on 15th December and after the announcement by management that it will divest its operations in Thailand).
- S&P needs 90 days to assess the evolution of Casino's results and financial position (i.e. Casino probably has this deadline to undertake convincing asset disposals). At first sight, if Casino were to lose its investment grade status, its interest charge in France would increase by around EUR100m, amputating the domestic FCF (as a reminder, guidance for this is for 2016 FCF after financial expenses and dividends "above EUR200m" in France).
- Management must reassure that it is able to quickly put in place a clear strategy of deleveraging through outright disposals (and not financial engineering) on very good multiples (we are waiting to see the exit terms from Vietnam and Big C). The market now has to rely on Casino's track record in terms of asset disposals (see page 2).

VALUATION

- Our own Fair Value is the average between an SOTP (EUR 41) and a DCF (EUR 68). Following our latest adjustments, it therefore works out to EUR54 vs EUR69.

Bloomberg	CO FP
Reuters	CASP.PA
12-month High / Low (EUR)	87.3 / 38.2
Market Cap (EURm)	4,532
Ev (BG Estimates) (EURm)	14,988
Avg. 6m daily volume (000)	699.9
3y EPS CAGR	-11.9%

	1 M	3 M	6 M	31/12/14
Absolute perf.	-13.0%	-28.3%	-42.0%	-47.6%
Food Retailing	-5.3%	-7.2%	-14.2%	3.4%
DJ Stoxx 600	-8.3%	-8.6%	-17.5%	-3.7%

YEnd Dec. (EURm)	2014	2015e	2016e	2017e
Sales	48,492	45,943	44,879	47,304
% change		-5.3%	-2.3%	5.4%
EBITDA	3,191	2,481	2,521	2,727
EBIT	1,737	1,587	1,518	1,609
% change		-8.6%	-4.3%	6.0%
Net income	556.0	319.6	362.7	402.1
% change		-42.5%	13.5%	10.9%

	2014	2015e	2016e	2017e
Operating margin	4.6	3.3	3.4	3.4
Net margin	1.1	0.7	0.8	0.9
ROE	NM	NM	NM	NM
ROCE	7.1	4.7	4.6	4.8
Gearing	37.3	38.6	40.7	40.5

(EUR)	2014	2015e	2016e	2017e
EPS	4.43	2.30	2.68	3.03
% change	-	-48.2%	16.6%	13.0%
P/E	9.0x	17.4x	15.0x	13.2x
FCF yield (%)	15.3%	0.0%	3.2%	11.4%
Dividends (EUR)	3.12	3.12	3.12	3.12
Div yield (%)	7.8%	7.8%	7.8%	7.8%
EV/Sales	0.4x	0.3x	0.3x	0.3x
EV/EBITDA	5.4x	6.0x	5.9x	5.6x
EV/EBIT	10.0x	9.4x	9.8x	9.5x



(continued net page)

Asset disposal programme of Casino over the last years

€2bn disposal programme announced in March 2006, for completion by	Amount
Disposal of 11 warehouses	188
Disposal of treasury stock	48
Mercialys	240
Disposal of Saint Etienne head office	86
Unwinding Cora equity swap	253
38% of Feu Vert	90
Poland	827
Taiwan (50%)	50
Smart & Final (55%)	351
Disposal of real estate in France and La Réunion	635
Total programme 2006	2 768

€1bn disposal programme announced in March 2009, for completion by	Amount
Super de Boer (Netherlands) /Laurus	400
Mature real estate	100
Venezuela indemnification (60%)	276
Exito capital increase/end of Carulla Vivero put	195
Total programme 2009	971

€700m disposal programme announced in November10, extended to	Amount
Exito capital increase	430
Mature real estate / other real estate (Venezuela indemnification 40%)	370
GPA equity swap (3% of capital)	200
Total programme 2010/2011	1 000

€1.5bn programme announced in March 2012 and to be completed over	Amount
Mercialys	700
Capital increase and disposals of treasury stocks	400
Disposal of financial and real estate assets	200
Others	100
Total programme 2012	1 500

Source: Company Data; Bryan, Garnier & Co ests.

[Click here to download](#)



Analyst :
Antoine Parison
33(0) 1 70 36 57 03
aparison@bryangarnier.com

Sector Team :
Nikolaas Faes
Loïc Morvan
Cédric Rossi
Virginie Roumage

Sector View

Video Games

US packaged software sales in December and CY15

	1 M	3 M	6 M	31/12/14
Softw. & Comp. SVS	-5.5%	3.8%	-1.1%	18.9%
DJ Stoxx 600	-8.3%	-8.6%	-17.5%	-3.7%

*Stoxx Sector Indices

Companies covered

GAMELOFT	BUY	EUR6.7
<i>Last Price</i>	EUR5.1	<i>Market Cap.</i> EUR434m
UBISOFT	BUY	EUR37
<i>Last Price</i>	EUR24.22	<i>Market Cap.</i> EUR2,694m

The NPD Group has released data for December's packaged video games sales in the US. Hardware sales were down 3% Y/Y in Dec. and 2% in CY15 (the PS4 was the top-selling console for the 10th time). Packaged software was down 6% in Dec. and 4% in CY15 (vs. BG ests: +5%e and stable), mainly due to declines in handheld and last generation consoles and the strong trend towards digital. Activision Blizzard's *Call of Duty: Black Ops III* was the best-selling game. Note that calendar Q4 represented 49.2% of CY sales (Oct. 6.5%, Nov. 19.2% and Dec. 23.4%). We are making no change to recommendations for our sector coverage: Buy on UBISOFT with a FV of EUR37 and GAMELOFT with a FV of EUR6.7. Speculation has heightened now that Vivendi has sold its remaining 5.7% stake in Activision Blizzard (net proceeds of -EUR1bn). We believe in this and our FVs reflect minimum prices for potential public offers.

ANALYSIS

- On Thursday overnight, the NPD Group released its monthly sales report for December's packaged video games in the US (5-week period ending on 2nd January, 2016). Bear in mind that these numbers only represent a fraction of the industry (i.e. around 50% of spending). NPD only tracks new games sold at US retailers. This does not include second-hand software, mobile, and digital. As such, it simply gives an insightful glimpse of a much more dynamic industry. Revenue in the sector was down 1% over one year at USD3.22bn (stable in CY15): 1/ Hardware -6% Y/Y at USD1.24bn (-4% in CY15: with -32% in handheld hardware, -71% in 7th-gen and +4% in 8th-gen home console hardware sales). The PS4 was the best-selling platform in the US for the 10th time YTD (thanks to PS4 *Star Wars Battlefront/UC* bundles with USD50 price cut to USD300 over 6-19 Dec., and despite a USD50 price cut for the Xbox One making an entry price at USD300 over 9-26 Dec.) and totalled 35.9m units sold to consumers worldwide since its launch (of which 5.7m during the holiday season). Note that Dec. 2015 was the best month ever for Xbox One, PS4 and Wii U total hardware unit sales; and 2015 the best year for PS4 and Xbox One. 2/ Software -3% Y/Y at USD1.21bn (-2% in CY15: with -34% in handheld software, -53% in 7th-gen and +52% in 8th-gen home console software sales), i.e. below our +5%e (stable sales est. for CY15; no consensus). Activision Blizzard's *Call of Duty: Black Ops III* was the top-selling game (a yearly well-established game franchise) significantly outselling EA's *Star Wars: Battlefront*. 3/ Accessories +10% Y/Y at USD761.7m (+12% in CY15), mainly thanks to peripherals, interactive toys, points, subscription cards sales.
- Worth noting on the software side in December: 1/ a fairly unfavourable base effect (-2% in Dec. 2014); 2/ *Call of Duty: Black Ops III* (Activision Blizzard) was the top-selling game of the month for the second time in a row; 3/ home console game sales were down 1%, and handheld game sales dropped 40%; 4/ 8th-gen console game sales increased 48% while the 7th-gen fell 54%; 5/ Dec. 2015 was the best month on record for PS4 and Xbox One, and the second-best for the Wii U in terms of new physical software unit sales; 6/ Dec. 2015 was the best month of total 8th-gen physical software sales; 7/ the growing transition towards digital (gamers are more and more comfortable with downloading games, all the more so with the highly connected home consoles).
- Bear in mind that the NPD Group doesn't track: 1/ digital game sales; and 2/ games packed-in with consoles (there were compelling bundles in December).

VALUATION

- UBISOFT: We are maintaining our Buy recommendation and FV of EUR37** (we value the entire cycle). This is derived from 12m fwd average multiples for Ubisoft's past two console cycles applied to our FY16-17 estimates to which we have added a 15% premium (justified by: 1/ contrary to the past, the current cycle includes ~40% of digital revenues which are more recurring and 25% more profitable, and 2/ Ubisoft is now benefiting from other entertainment revenues linked to the strength of its IPs).
- GAMELOFT: We are maintaining our Buy recommendation and FV of EUR6.7** (we value the entire cycle). We have applied an EV/sales of 2x to our FY16 estimate for Gameloft (i.e. a 20% discount to the recent acquisition multiple of King digital by Activision Blizzard).

NEXT CATALYSTS

- UBISOFT: Q3 sales** on 11th February, 2016 (after trading).
- GAMELOFT: FY sales** on 28th January, 2016 (after trading).



Top ten selling games in December 2015 by platform in the US

Rank	Games	Consoles	Publisher
1	<i>Call of Duty: Black Ops III</i>	Xbox One, PS4, Xbox 360, PS3, PC	Activision Blizzard
2	<i>Star Wars: Battlefront</i>	Xbox One, PS4, PC	Electronic Arts
3	<i>Fallout 4</i>	PS4, Xbox One, PC	Bethesda Softworks
4	<i>Madden NFL 16</i>	PS4, Xbox One, Xbox 360, PS3	Electronic Arts
5	<i>NBA 2K 16</i>	PS4, Xbox One, Xbox 360, PS3	Take-Two Interactive
6	<i>Grand Theft Auto V</i>	PS4, Xbox One, Xbox 360, PS3, PC	Take-Two Interactive
7	<i>Tom Clancy's Rainbow Six: Siege</i>	Xbox One, PS4, PC	Ubisoft
8	<i>Minecraft</i>	Xbox 360, Xbox One, PS4, PS3	Microsoft
9	<i>Minecraft: Story Mode – A Telltale Game Series</i>	Xbox 360, Xbox One, PS4, PS3	Telltale Games
10	<i>FIFA 16</i>	PS4, Xbox One, Xbox 360, PS3	Electronic Arts

N.B.: games bundled with hardware are not tracked by the NPD Group

Sources: NPD Group; Bryan, Garnier & Co.

- *Call of Duty: Black Ops III* (Activision Blizzard) was the top-selling game in Dec. and CY15.
- Electronic Arts was the publisher of the month and CY15, with three titles in the TOP 10.
- Ubisoft ranked only 1 game in Dec. (*Rainbow Six: Siege*) and none in CY15.


Y/Y % change in retail software sales in the US from 2000 to 2015 (in value, at constant scope)

%	2000	2001	2002	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015
January	2	16	4	0	18	0	-5	53	12	10	-12	-5	-38	1	-25	6
February	5	-11	45	-5	5	13	-12	32	48	9	-15	-5	-23	-36	-9	7
March	20	-15	33	8	-6	31	-8	16	64	-17	10	-16	-25	-1	-27	-3
April	27	-13	11	39	-3	9	16	-1	69	-22	-22	26	-42	-17	-10	13
May	4	10	31	20	-17	30	-10	33	42	-17	4	-19	-32	-31	57	-25
June	4	23	27	-9	12	2	15	22	61	-29	-15	-12	-29	-10	-3	21
July	-1	26	11	4	27	-10	19	11	41	-26	-8	-17	-23	-19	-15	0
August	-12	18	43	4	1	0	18	23	13	-15	-14	-34	-9	23	-21	-10
September	-26	-8	50	-10	44	-24	29	47	-6	5	-6	3	-18	52	-36	-3
October	13	-20	74	-15	35	-24	1	40	36	-18	6	3	-25	12	-27	-3
November	1	28	7	7	11	-17	14	63	11	-3	3	11	-11	-24	-1	-7
December	-9	24	7	13	-1	-3	6	37	15	-7	-8	-14	-26	-17	-2	-3
Total	-1	10	21	5	8	-3	7	34	27	-10	-6	-6	-23	-9	-12	-2

Sources: NPD Group; Bryan, Garnier & Co.

- Packaged software sales were down 3% in December (vs. BG: +5%e)
- Packaged software sales were down 2% in CY15 (vs. BG: stable), after -12% in CY14.
- Physical sales account for 50%e of the US consumer spend on the industry (35/40%e in Europe).
- Combined PS4/Xbox One sales are 47% higher than Xbox 360/PS3 over the past 26 months.

US retail software contribution in CY15 sales per month



Sources: NPD Group; Bryan, Garnier & Co.

[Click here to download](#)



Analyst :
Richard-Maxime Beaudoux
33(0) 1.56.68.75.61
rmbeaudoux@bryangarnier.com

Sector Team :
Thomas Coudry
Gregory Ramirez
Dorian Terral

TMT

Axway Software

Price EUR22.40

Acquisition of Appcelerator

Fair Value EUR30 (+32%)

BUY

Bloomberg	AXW FP
Reuters	AXW PA
12-month High / Low (EUR)	25.7 / 14.8
Market Cap (EURm)	461
Avg. 6m daily volume (000)	11.00

	1 M	3 M	6 M	31/12/14
Absolute perf.	-10.4%	-0.9%	9.3%	35.8%
Softw. & Comp.				
SVS	-5.5%	3.8%	-1.1%	18.9%
DJ Stoxx 600	-8.3%	-8.6%	-17.5%	-3.7%
	2014	2015e	2016e	2017e
P/E	13.7x	12.6x	11.3x	10.1x
Div yield (%)	1.9%	1.9%	2.1%	2.3%

ANALYSIS

- **This morning Axway announced the acquisition of Appcelerator for an undisclosed sum.** Founded in 2006 with headquarters in San Jose (California), Appcelerator develops and sells a mobile engagement platform which help companies to create mobile apps, integrate them with existing systems using APIs, manage back-end services and optimise them with comprehensive analytic tools. It is handling 2bn mobile API calls per month and powers apps running on over 350m mobile devices.
- **This is not a big acquisition, but helps Axway's digital engagement strategy.** We understand Appcelerator is a small company, of a size similar to that of Vordel when it was acquired in 2012 (around an est. EUR10m), with an SaaS revenue model. We doubt the company is profitable given its size. The acquisition price was not disclosed but this kind of target is usually sold for several times sales. Finally, Appcelerator provides Axway with a stronger Digital Engagement strategy, by adding the mobile app development and analytical layers to the API integration layer brought by Vordel.

VALUATION

- Axway's shares are trading at est. 7.3x 2016 and 5.9x 2017 EV/EBIT multiples

NEXT CATALYSTS

- FY15 results on 24th February after trading.

[Click here to download](#)Gregory Ramirez, gramirez@bryangarnier.com

Healthcare

Bone Therapeutics

Price EUR16.98

Fair Value EUR29 (+71%)

BUY-Top Picks

Bloomberg	BONE.FP
Reuters	BONE.PA
12-month High / Low (EUR)	24.1 / 16.0
Market Cap (EURk)	116,279
Avg. 6m daily volume (000)	4.00

	1 M	3 M	6 M	31/12/14
Absolute perf.	-5.7%	-17.8%	-21.4%	ns
Healthcare	-6.3%	-4.4%	-15.4%	4.3%
DJ Stoxx 600	-8.3%	-8.6%	-17.5%	-3.7%

	2014	2015e	2016e	2017e
P/E	x	x	x	x
Div yield (%)	NM	NM	NM	NM

ANALYSIS

- Bone Therapeutics has announced this morning the initiation of a phase IIa study in patients suffering from multiple delayed-union fractures. The trial aims to assess both efficacy and safety of two to four minimally invasive percutaneous doses of ALLOB at two to four sites on either the same or different long bones and should enrol 12 patients. Recruitment of the 12 patients with 9 sites opened in Belgium and Germany is expected to be completed towards the year-end with a readout by mid-2017. Patients are to be evaluated at six months by CT-scan or X-ray. We believe that a >2 points improvement has been retained as has been the case for the ongoing phase IIa non-union trial.
- This extension of the phase IIa trial in delayed-union patients should offer additional data on the use of ALLOB at higher doses i.e. up to 200⁶ cells while 100⁶ cells has been the maximum studied so far. As such, we are not ruling out the prospect of patients suffering from multiple fractures being included in the phase III trial, potentially broadening the label of Bone Therapeutics' allogeneic product upon approval.

VALUATION

- We are reiterating our BUY recommendation and EUR29 Fair Value.
- We are making no change to our estimates and will wait for the DSMB review in delayed-union patients to include multiple delayed union fractures in our estimates. Note that we estimate the multiple delayed-union fracture market represents 10-20% of the monofocal delayed-union market

NEXT CATALYSTS

- Q1 2016: interim efficacy analysis for the first patients' cohort suffering from severe Osteoporosis
- Q1 2016: Results from the second patients' cohort from the delayed-union phase IIa trial followed by DSMB's interim review on the first 16 patients. Note that the study could be stopped prematurely should 12 out of 16 patients be responders. Four patients (first cohort) have already been qualified as responders.

[Click here to download](#)

Hugo Solvet, hsolvet@bryangarnier.com

Insurance

Coface

Price EUR9.09

Xavier Durand to replace Jean-Marc Pillu as CEO next month

Fair Value EUR10.5 (+16%)

NEUTRAL

Bloomberg	COFA.FP
Reuters	COFA.PA
12-month High / Low (EUR)	11.9 / 7.4
Market Cap (EURm)	1,440
Avg. 6m daily volume (000)	153.2

	1 M	3 M	6 M	31/12/14
Absolute perf.	-0.5%	18.0%	-18.1%	-17.2%
Insurance	-8.0%	-2.5%	-11.4%	3.0%
DJ Stoxx 600	-8.3%	-8.6%	-17.5%	-3.7%

	2014	2015e	2016e	2017e
P/E	11.3x	10.9x	10.4x	9.6x
Div yield (%)	5.3%	5.5%	5.7%	6.2%

ANALYSIS

- The company has announced on Friday night that Jean-Marc Pillu, 60 next March, will step down once 2015 accounts have been approved (9th February 2016), and that Xavier Durand, 52, will take over as CEO at that date.
- Jean-Marc Pillu arrived 5 years ago and has restructured the company into a pure player in credit insurance, driving operating performances up, improving processes, and successfully led the IPO. But remember that Coface is currently in a moving situation, with the loss of public guarantee activities due this year (EUR33m net operating profit impact, or 18% the 2014-2015e numbers) and the necessity to engage a restructuring plan (due 9th February).
- The mission of Xavier Durand, currently Director of Strategy and Growth at GE Capital, is to "reinforce commercial activity", and "implement the necessary structural adaptations in order to continue to improve the group's operational efficiency". The 9th February will definitely be critical for the investment case of the company.

VALUATION

- Based on our current estimates, our SOTP is EUR10.5.

NEXT CATALYSTS

- FY 2015 will be released on 9th February 2016.

[Click here to download](#)

Olivier Pauchaut, opauchaut@bryangarnier.com

Food & Beverages

Pernod Ricard

Price EUR97.09

Pernod Ricard gained US approval for Havana Club trademark

Fair Value EUR122 (+26%)

BUY-Top Picks

Bloomberg	RI FP
Reuters	PERP.PA
12-month High / Low (EUR)	117.3 / 88.3
Market Cap (EURm)	25,770
Avg. 6m daily volume (000)	545.9

	1 M	3 M	6 M	31/12/14
Absolute perf.	-5.2%	-2.1%	-11.2%	5.2%
Food & Bev.	-5.7%	-3.2%	-5.8%	9.2%
DJ Stoxx 600	-8.3%	-8.6%	-17.5%	-3.7%

	06/15	06/16e	06/17e	06/18e
P/E	19.5x	17.5x	16.3x	15.2x
Div yield (%)	1.9%	2.1%	2.2%	2.4%

ANALYSIS

- In recent days, the US Patent and Trademark Office has recognised the Havana Club trademark. This was not renewed when it expired in 2006 due to the "Bacardi bill" preventing the recognition of any trademark rights confiscated by a government without compensation, as is the case for Havana Club. The Puerto Rican group had bought the brand in 1997 from the Arechabala family, which went into exile after the Cuban revolution.
- The decision will enable Pernod Ricard to export Havana Club when the US congress lifts the current embargo on Cuban goods. The US accounts for 40% of global rum sales, making it the first rum market in the world. Havana Club has two assets to capture a share of the market in which Bacardi is currently the leader: 1/ its Cuban origin as it is the only brand that is 100% Cuban and 2/ its price positioning, i.e. high-end premium and super premium.

VALUATION

- In our note "Cuba Libre", we calculate that the lifting of the embargo could lead to upside of 10% relative to our current Fair Value of EUR122.
- However the move could add as much as 14%. In a bleak scenario, there is still a 5% uplift.

NEXT CATALYSTS

- H1 2015/16 results due on February 11th

[Click here to download](#)

Virginie Roumage, vroumage@bryangarnier.com

BG's Wake Up Call

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

BUY	Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements including a SWOT analysis, positive momentum, technical aspects and the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
NEUTRAL	Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.
SELL	Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements including a SWOT analysis, positive momentum, technical aspects and the sector backdrop. Every subsequent published update on the stock will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 57.6%

NEUTRAL ratings 33.3%

SELL ratings 9.1%

Bryan Garnier Research Team

Healthcare Team	Pharmaceuticals	Eric Le Berrigaud <i>(Head of Equities)</i>	33 (0) 1 56 68 75 33	eleberrigaud@bryangarnier.com
	Biotech/Medtech	Mickael Chane-Du	33 (0) 1 70 36 57 45	mchanedu@bryangarnier.com
	Medtech/Biotech	Hugo Solvet	33 (0) 1 56 68 75 57	hsolvet@bryangarnier.com
Consumer Team	Luxury/Consumer Goods	Loïc Morvan	33 (0) 1 70 36 57 24	lmorvan@bryangarnier.com
	Beverages	Nikolaas Faes	33 (0) 1 56 68 75 72	nfaes@bryangarnier.com
	Retailing	Antoine Parison	33 (0) 1 70 36 57 03	aparison@bryangarnier.com
	Luxury /Consumer Goods	Cedric Rossi	33 (0) 1 70 36 57 25	crossi@bryangarnier.com
TMT	Food & Beverages	Virginie Roumage	33 (0) 1 56 68 75 22	vroumage@bryangarnier.com
	Video Games / Payments	Richard-Maxime Beaudoux	33 (0) 1 56 68 75 61	rmbeaudoux@bryangarnier.com
	Telecom	Thomas Coudry	33(0) 1 70 36 57 04	tcoudry@bryangarnier.com
	Software & IT Services	Gregory Ramirez	33 (0) 1 56 68 75 91	gramirez@bryangarnier.com
Utilities	Semiconductor	Dorian Terral	33 (0) 1 56 68 75 92	dterral@bryangarnier.com
Insurance		Xavier Caroen	33 (0) 1 56 68 75 18	xcaroen@bryangarnier.com
Hotels/Business Services		Olivier Pauchaut <i>(Head of Research)</i>	33 (0) 1 56 68 75 49	opauchaut@bryangarnier.com
Construction/ Infrastructures Building Materials		Bruno de La Rochebrochard	33 (0) 1 56 68 75 88	bdelarochebrochard@bryangarnier.com
		Eric Lemarié	33 (0) 1 70 36 57 17	elemarie@bryangarnier.com
Marketing		Sophie Braincourt	33(0) 1 56 68 75 36	sbraincourt@bryangarnier.com
Market Data & Information Systems Manager		Eric Monnier	33(0) 1 56 68 75 63	emonnier@bryangarnier.com

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

London	Paris	New York	Geneva	New Delhi
Beaufort House	26 Avenue des Champs Elysées	750 Lexington Avenue	rue de Grenus 7	The Imperial Hotel
15 St Botolph Street	75008 Paris	New York, NY 10022	CP 2113	Janpath
London EC3A 7BB	Tel: +33 (0) 1 56 68 75 00	Tel: +1 (0) 212 337 7000	Genève 1, CH 1211	New Delhi 110 001
Tel: +44 (0) 207 332 2500	Fax: +33 (0) 1 56 68 75 01	Fax: +1 (0) 212 337 7002	Tel +4122 731 3263	Tel +91 11 4132 6062
Fax: +44 (0) 207 332 2559	Regulated by the Financial Conduct	FINRA and SIPC member	Fax+4122731 3243	+91 98 1111 5119
Authorised and regulated by	Authority (FCA) and l Autorité de		Regulated by the	Fax +91 11 2621 9062
the Financial Conduct Authority	Contrôle prudentiel et de resolution		FINMA	
(FCA)	(ACPR)			



BRYAN, GARNIER & CO

Disclaimer:

Bryan Garnier & Co Limited, registered in England Number 03034095 with registered office : Beaufort House 15 St Botolph Street, London EC3A 7BB , United Kingdom and its MIFID branch registered in France Number 452 605 512 with registered office : 26, Avenue des Champs Elysées 75008 Paris , France. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firms' prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Important information - This report may contain "Independent" and "Corporate/Non-independent" research reports.

Unless stated otherwise, documents in this report are classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

Independent investment research reports:

Independent investment research reports are prepared by Bryan Garnier & Co Limited and are distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports are provided for information purposes only and do not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person. The information and opinions contained in these reports have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in these reports are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of these reports. Information may be available to the Firm and/or associated companies which is not reflected in these reports. The Firm or an associated company may have a consulting relationship with a company which is the subject of these reports.

Corporate or Non-Independent investment research reports:

Non-independent research reports are prepared by Bryan Garnier & Co Limited and are being distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports have been sent to you for marketing purposes only and are non-independent research within the meaning of the FCA rules. These reports are not being held out as an objective or independent explanation of the matters contained in them and should not be treated as such. These reports have not been prepared in accordance with the legal requirements designed to promote the independence of investment research. The Firm is not subject to any prohibition on dealing ahead of the dissemination of investment research.

These reports usually focus on emerging European growth companies. The contents of these reports as well as the other research documents on emerging growth stocks do not contain the Firm's usual stock ratings. The intrinsic value analysis is presented to provide a framework for stock valuation and discussion, and represents an estimated value on the date of publishing, which may be subject to change without notice.

The Firm's rationale for not having ratings on the stock includes the fact that such stock may have limited market capitalisation and liquidity and while the Firm may express an opinion on the near-term movement of the stock, what action investors should take depends on many factors, including liquidity/risk tolerance, holdings timeframe and investment philosophy. Emerging companies evolve rapidly with a continuous flow of information that can significantly impact the company and in the Firm's opinion this cannot be reflected by a periodic rating. Additionally, the Firm may have an advisory relationship with the company which is the subject of these reports, including for the production of sponsored research, and may expect to receive or intend to seek compensation for investment banking services from that company in the six months following the date of these reports.

To the fullest extent permitted by law, the Firm does not accept any liability whatsoever for any direct or consequential loss arising from any use of the information contained in these reports. Information may be available to the Firm which is not reflected in these reports. They are provided for information purposes only and do not constitute an offer or solicitation to buy or sell any of the securities discussed in them. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC, 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000.

This Report is based on information obtained from sources that Bryan Garnier & Co. Ltd. believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co. Ltd. and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available....